The antitumor effects of muramyl tripeptide phosphatidylethanolamine, incorporated within the lipophilic phase of liposomes (lipMTP-PE) were studied using a model of liver metastasis of colon cancer in the rat. Intravenous immunotherapy with lipMTP-PE, when started 2 days before the inoculation of tumor cells and given twice a week, significantly reduced subsequent tumor growth in the liver. The main effect of treatment appeared to be a substantial local increase in the number of tumoricidal macrophages and lymphocytes. Tumor cell lysis by isolated macrophages in vitro, however, appeared not to be elevated above the level triggered by tumor growth alone. Therefore, the observed therapeutic effect of lipMTP-PE probably results from a combination of (1) an increase in the number of cytotoxic macrophages at the onset of metastatic growth in the liver, thus increasing the probability of lethal contacts between tumoricidal effectors and tumor cells and (2) indirect effects of lipMTP-PE, via the induction of cytokine production by liver macrophages, leading to increased numbers and/or activity of cytotoxic lymphocytes and natural killer cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hughes KS, Rosenstein RB, Songhorabodi S, et al. 1988, Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of long-term survivors. Dis Colon Rect, 31, 1–4.
Greenway B, 1988, Hepatic metastases from colorectal cancer: resection or not? Br J Surg, 75, 513–9.
Phillips NC, 1990, Macrophages, metastasis and immunity. Prog Clin Biol Res, 354, 257–70.
Fidler IJ and Schroit AJ, 1988, Recognition and destruction of neoplastic cells by activated macrophages; discrimination of altered self. Biochim Biophys Acta, 948, 151–73.
Daemen T, Veninga A, Roerdink FH and Scherphof GL, 1986, In vitro activation of rat liver macrophages to tumoricidal activity by free or liposome-encapsulated muramyl dipeptide. Cancer Res, 46, 4330–6.
Daemen T, Dontje BHJ, Veninga A, Scherphof GL and Oosterhuis WL, 1990, Therapy of murine liver metastases by administration of MDP encapsulated in liposomes. Sel Cancer Ther, 6, 63–71.
Liebes L, Walsh CM, Chachoua A et al. 1992, Modulation of monocyte functions by MTP-PE in a phase II study in patients with metastatic melanoma. J Natl Cancer Inst, 84, 694–9.
Kleinerman ES, Raymond AK, Bucana CD et al. 1992, Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol Immunother, 34, 211–20.
Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS and Jaffe N, 1992, Phase II study of liposomal MTP-PE in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol, 10, 1310–6.
Brodt P, Blore J, Phillips NC, Munzer JS and Rioux JD, 1989, Inhibition of murine hepatic tumor growth by liposomes containing a lipophilic muramyl dipeptide. Cancer Immunol Immunother, 28, 54–8.
Phillips NC and Tsao MS, 1989, Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative. Cancer Res 49, 936–9.
Hoedemakers RMJ, Vossebeld P, Daemen T and Scherphof GL, 1993, Functional characteristics of the rat liver macrophage population after a single intravenous injection of liposome-encapsulated muramyl peptides. J Immunother, 13, 252–60.
Phillips NC, Rioux J and Tsao M-S, 1988, Activation of murine Kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide. Hepatology 8, 1046–50.
Asano T and Kleinerman ES, 1993, Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother, 14, 286–92.
Verma JN, Rao M, Amselem S et al. 1992, Adjuvant effects of liposomes containing Lipid A: enhancement of liposomal antigen presentation and recruitment of macrophages. Inflam Immunol, 60, 2438–44.
Daemen T, Huitema S, Koudstaal J, Scherphof GL and Hardonk MJ, 1989, Population kinetics of rat liver macrophages after intravenous administration of liposome-encapsulated MDP. In: Wisse E, Knook DL and Decker K, eds. Cells of the Hepatic Sinusoid, Vol 2. Rijswijk, The Netherlands: The Kupffer Cell Foundation, pp. 400–5.
Talmadge JE, Schneider M, Collins M et al. 1985, Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE. J. Immunol., 135, 1477–83.
Thomas C, Nijenhuis AM, Daemen T and Scherphof GL, 1993, Tumoricidal and kinetic response of rat Kupffer cells to challenge with syngeneic colon adenocarcinoma cells or liposomal immunomodulators. In: Knook DL and Wisse E, eds. Cells of the Hepatic Sinusoid, Vol 4, Leiden, The Netherlands: The Kupffer Cell Foundation, pp. 496–9.
Thomas C, Nijenhuis AM, Dontje B, Daemen T and Scherphof GL, 1995, Tumoricidal response of liver macrophages isolated from rats bearing liver metastases of colon adenocarcinoma. J Leuk Biol, 57, 617–23.
Marquet RL, Westbroek DL, Jeekel J, 1993, Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. Int J Cancer, 33, 689–92.
Thomas C, Nijenhuis AM, Timens W et al. 1993, Liver metastasis model of colon cancer in the rat. Immunohistochemical characterization. Inv Metastasis, 13, 102–12.
Sone S, Utsugi T, Tandon T, Ogawara M, 1986, A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state. Cancer Immunol Immunother, 22, 191–6.
Dijkstra CD, Döpp EA, Joling P and Kraal G, 1984, The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in rats recognized by monoclonal antibodies ED1, ED2 and ED3. Immunol, 54, 589–99.
Mason DW, Arthur RP, Dallman MJ et al. 1983, Functions of rat T-lymphocyte subsets isolated by means of monoclonal antibodies. Immunol Rev, 74, 57–64.
Jeannin J-F, Onier N, Lagadec P et al. 1991, Antitumor effect of synthetic derivatives of Lipid A in an experimental model of colon cancer in the rat. Gastroenterol, 101, 726–33.
Heuff G, Oldenburg HSA, Boutkan H et al. 1993, Enhanced tumor growth in the rat liver after selective elimination of Kupffer cells. Cancer Immunol Immunother, 37, 125–30.
Maeda M, Asano T and Kleinerman ES, 1993, Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide. Cancer Immunol Immunother, 37, 203–8.
Bouwens L and Wisse E, 1988, Tissue localization and kinetics of pit cells or large granular lymphocytes in the liver of rats treated with biological response modifiers. Hepatol, 8, 46–52.
Daemen T, Dontje BHJ, Regts J and Scherphof GL, 1993, Chemoimmunotherapy of murine liver metastases with 5-Fluorouracil in combination with liposome encapsulated muramyl dipeptide. J Immunother, 13, 31–5.
Laude M, Russo KL, Mokyr, MB and Dray S, 1993, Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemo-immunotherapy. Cancer Immunol Immunother, 36, 229–36.
Asano T, Fujimaki W, McWatters A et al. 1993, Effect of adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression. Cancer Immunol Immunother, 37, 408–11.
Daemen T, Veninga A, Regts J and Scherphof GL, 1991, Maintenance of tumoricidal activity and susceptibility to reactivation of subpopulations of rat liver macrophages. J Immunother, 10, 200–6.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thomas, K., Nijenhuis, A.M., Dontje, B.H.J. et al. Antitumor reactivity induced by liposomal MTP-PE in a liver metastasis model of colon cancer in the rat. Clin Exp Metast 13, 328–336 (1995). https://doi.org/10.1007/BF00121909
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00121909